Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Suboxone

- PMLiVE

US Supreme Court asked to block Purdue Pharma bankruptcy settlement

The company has been blamed for fuelling the opioid crisis with the promotion of its drug OxyContin

- PMLiVE

As the opioid crisis grabs the headlines, the search for safe treatments continues

Indivior’s Gilles Picard charts a path to greater patient access and new therapies

- PMLiVE

Reckitt hammered by $1.4bn opioid settlement bill

Case centres on Subaxone marketing practices

- PMLiVE

Indivior push to diversify boosted by schizophrenia drug approval

Perseris will face competition from Lundbeck/Otsuka’s Abilify Maintena and J&J’s Invega Sustenna

- PMLiVE

FDA panel backs Indivior’s drug to fight opioid addiction

The former RB pharma unit hopes for sales in the $1bn region

- PMLiVE

Indivior slumps as patent dispute rises US generic spectre

The RB spin out will appeal against the ruling

- PMLiVE

Reckitt to spin-off pharma unit as Indivior

Demerged business will focus on opioid dependence product Suboxone

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links